This makes these drugspotential candidates for breaking cancer stem cell resistance andtargeting these cells. According to ourRT-qPCR results, especially in the CD133+ population, the suppressionof the expression of both genes indicates that niclosamide treatmentmay break the drug resistance in this resistant population. This evidence concerns the gene PROM1 and cancer.